The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | Utilizing molecular data to refine diagnoses in myeloid malignancies with overlapping features
Sanam Loghavi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the utilization of molecular data to refine diagnoses in myeloid malignancies with overlapping features. She comments on the importance of balancing molecular diagnostics with practicality in real-world settings, highlighting the need for classification systems to be widely applicable. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
I think there’s a very fine balance between doing this and still remaining practical in a real-world setting. I think, of course, with the revolution that has happened in molecular diagnostics in the last several years, we’ve really learned that the molecular drivers of disease are what determine the outcome. But I think that said, we still want our classification systems to be practical and utilized in every setting, including resource-limited settings...
I think there’s a very fine balance between doing this and still remaining practical in a real-world setting. I think, of course, with the revolution that has happened in molecular diagnostics in the last several years, we’ve really learned that the molecular drivers of disease are what determine the outcome. But I think that said, we still want our classification systems to be practical and utilized in every setting, including resource-limited settings. So I think as pathologists, we make an effort to make the guidelines and the classifications widely applicable and try to come up with surrogate markers of underlying molecular features that help every pathologist make a diagnosis as accurate as possible.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
